UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 11, 2019

 

 

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-55453   45-2552528
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)

 

6320 Canoga Avenue, 15th Floor

Woodland Hills, CA 91367

(Address of principal executive office)(Zip Code)

 

Registrant’s telephone number, including area code: (800) 489-4774

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.0001   ENDV   OTCQB

 

 

 

   
 

 

Item 3.03 Material Modification to Rights of Security Holders.

 

On December 11, 2019 a certificate of amendment to the Registrant’s Certificate of Incorporation was filed to affect a one thousand for one reverse stock split (“Reverse Stock Split”). The Registrant has been advised by FINRA that the Reverse Stock Split will become effective on December 20, 2019. For the details of the Reverse Stock Split, the reader is directed to the Certificate of Amendment which is an exhibit hereto.

 

Item 9.01 Financial Statements and Exhibits.

 

  (a) Financial Statements

 

None

 

  (b) Exhibits

 

  3.1 Certificate of Amendment affecting Reverse Stock Split

 

   
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 18, 2019

 

  ENDONOVO THERAPEUTICS, INC.
     
  By: /s/ Alan Collier
   

Alan Collier

Chief Executive Officer